IGC Pharma Achieves 65% Enrollment In Phase 2 CALMA Trial For Alzheimer's Agitation

IGC Pharma said its Phase 2 CALMA trial of IGC‑AD1 for agitation in Alzheimer’s has reached 65% enrollment toward a 146‑patient target in the U.S. and Canada, with interim analyses reportedly showing clinically and statistically significant reductions in agitation—a prevalent symptom affecting over 76% of Alzheimer’s patients and an area with limited treatments. Enrollment has been accelerated via a hybrid strategy (≈25% recruited through targeted social media and 75% through clinical sites), and the company expects full enrollment in early 2026. IGC, which integrates AI across its drug development efforts, is also advancing TGR‑63 (anti‑amyloid) and early‑stage tau, neurodegeneration and metabolic programs; its stock closed at $0.29 yesterday, up 2.48% (12‑month range $0.25–$0.50).

Analysis

IGC Pharma has reached 65% enrolment in its Phase 2 CALMA trial of IGC-AD1, targeting 146 patients across the U.S. and Canada, with the company projecting full enrolment in early 2026. The company reports interim analyses demonstrating clinically and statistically significant reductions in agitation — a symptom affecting more than 76% of Alzheimer’s patients — positioning a cannabinoid-based candidate in a market with limited treatment options.

Enrollment has been accelerated via a hybrid strategy (approximately 25% of participants recruited through targeted social media and 75% through clinical sites), suggesting effective patient outreach, and IGC highlights AI integration across trial design and pipeline discovery. The broader pipeline includes TGR-63 (anti-amyloid) and early-stage tau, neurodegeneration and metabolic programs, while the stock closed at $0.29 (+2.48%) and has traded between $0.25 and $0.50 over the past 12 months; sentiment and market-impact scores are mildly positive (0.3).

Interim positive signals materially de-risk the program relative to preclinical stages but remain non-definitive; primary endpoint results and full safety data will determine commercial and regulatory prospects. Given the early-stage status, low share price and binary nature of clinical outcomes, timeline slippage, limited disclosure detail and trial execution are primary near-term risks to monitor.

Key Decisions for Investors

• Monitor enrolment progress and any detailed interim statistical disclosures closely and refrain from materially increasing exposure until primary endpoint data are available, consider the early-2026 enrolment target as a gating milestone
• Treat IGC as a high-risk, high-reward speculative biotech position and size allocations accordingly — limit position size to a small percentage of liquid biotech exposure or use position caps
• If forthcoming detailed interim or topline Phase 2 data confirm robust efficacy with an acceptable safety profile, consider adding to positions or initiating a tactical long trade, otherwise use strict stop-losses or avoid adding
• Watch for signs of operational execution (enrolment pace vs. target) and any partnership or licensing announcements that would materially derisk valuation and could trigger a re-rating